178
Participants
Start Date
July 28, 2024
Primary Completion Date
June 8, 2027
Study Completion Date
June 8, 2029
Radiotherapy
"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
Chemotherapy
For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
Immunotherapy
For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
RECRUITING
Departmeng of Urology, Peking University First Hospital, Beijing
RECRUITING
Department of Medical Oncology, Peking University First Hospital, Beijing
RECRUITING
Department of Radiotherapy Oncology, Peking University First Hospital, Beijing
Peking University First Hospital
OTHER